Apollo Endosurgery, Inc.: management transactions · United States · SEC (Form 4)

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. was a U.S.-based medical technology company focused on minimally invasive devices for therapeutic endoscopy and bariatric intervention. Before its delisting, the company traded on NASDAQ under the ticker APEN and was headquartered in Austin, Texas, United States. From an investor perspective, Apollo sat in the specialty medtech segment: a niche business model built around clinical innovation, procedure-specific adoption, and the long sales cycle typical of hospital-based devices. Its core addressable markets included gastroenterology, obesity treatment, and gastrointestinal defect management, giving the company exposure to areas where less invasive solutions can improve patient recovery and procedure efficiency. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1251769/000125176922000064/apen-20220630.htm?utm_source=openai)) Apollo was founded in 2005 and developed a portfolio centered on endoscopic and bariatric therapies designed to complement or replace more invasive surgery. Its best-known products included ORBERA, a temporary intragastric balloon for weight management; LAP-BAND, an adjustable gastric banding system used in obesity treatment; OverStitch, an endoscopic suturing platform; and X-Tack, an endoscopic closure system for gastrointestinal defects and stent fixation. The company also marketed systems used in endoscopic sleeve gastroplasty and other advanced GI procedures. This product mix positioned Apollo in a technically demanding segment with meaningful barriers to entry, including clinical evidence generation, physician training, reimbursement complexity, and regulatory clearance. ([builtinaustin.com](https://www.builtinaustin.com/company/apollo-endosurgery?utm_source=openai)) In competitive terms, Apollo’s appeal lay in its focused portfolio and in the clinical value proposition of minimally invasive care. Its tools were designed to help physicians close GI defects, manage complications, and treat obesity with lower procedural burden than traditional surgery. The business had a U.S. base but served international markets as well, so its commercial footprint was not limited to one geography even if the United States was the anchor market. Public disclosures in 2022 indicated particularly strong demand for the company’s defect-closure franchise, especially OverStitch and X-Tack, while obesity-related products remained an important strategic pillar. That combination suggests a company with concentrated product expertise rather than broad-based medtech diversification. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1251769/000125176922000080/a2022q3ex99-1er.htm?utm_source=openai)) The key recent corporate event was Boston Scientific’s agreement in November 2022 to acquire Apollo Endosurgery, followed by completion of the acquisition on April 4, 2023. As a result, Apollo no longer operates as an independent listed issuer, but its legacy remains important for understanding SEC Form 4 history and insider transaction analysis around the prior public company. In summary, Apollo Endosurgery was a small-cap, innovation-led medtech company founded in 2005, headquartered in Austin, Texas, listed on NASDAQ in the United States, and ultimately absorbed into Boston Scientific after its strategic assets in endoluminal surgery proved attractive to a larger global device platform. ([prnewswire.com](https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-apollo-endosurgery-inc-301688803.html?utm_source=openai))